The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Open accessAbstract
BACKGROUND: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. METHODS: We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. RESULTS: Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). CONCLUSIONS: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it has recently become apparent that vertebrate specific chromatin complexes such as the HUSH complex can be major regulators of the LINE-1 family of retrotransposons 218,219 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [219]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationCirculating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,595
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Lauro S, 1999, Anticancer Res, 19, 3511
- Chen X, 1999, Clin Cancer Res, 5, 2297
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Condello, V., Macerola, E., Ugolini, C., Napoli, L. D., Romei, C., Materazzi, G., Elisei, R., & Basolo, F. (2018) · Head & Neck · doi:10.1002/hed.25155 · Cited by 32
Huang, R. S. P., Xiao, J., Pavlick, D. C., Guo, C., Yang, L. F., Jin, D. X., Fendler, B. J., Severson, E. A., Killian, J. K., Hiemenz, M., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab176 · Cited by 34
Emerging ctDNA detection strategies in clinical cancer theranostics
Yi, K., Wang, X., Filippov, S. K., & Zhang, H. (2023) · Smart Medicine · doi:10.1002/smmd.20230031 · Cited by 34
Li, G., Zhang, Y., Li, K., Liu, X., Lu, Y., Zhang, Z., Liu, Z., Wu, Y., Liu, F., Huang, H. D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101666 · Cited by 35
Adamczyk, L. A., Williams, H., Frankow, A., Ellis, H. P., Haynes, H. R., Perks, C. M., Holly, J. M. P., & Kurian, K. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00174 · Cited by 31
Tanić, M., & Beck, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.017 · Cited by 32
Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer
Hu, W., Yang, Y., Zhang, L., Yin, J., Huang, J., Huang, L., Gu, H., Jiang, G., & Fang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.980 · Cited by 30
Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Yates, L. R., & Desmedt, C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2548 · Cited by 33
Murray, M. J., Watson, H. L., Ward, D. M., Bailey, S., Ferraresso, M., Nicholson, J. C., Gnanapragasam, V. J., Thomas, B., Scarpini, C. G., & Coleman, N. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0657 · Cited by 31
McEvoy, A. C., Pereira, M. R., Reid, A. L., Pearce, R. L., Cowell, L., Al‐Ogaili, Z., Khattak, M. A., Millward, M., Meniawy, T. M., Gray, E. S., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26451 · Cited by 31
Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects
Payne, K. F. B., Brooks, J. M., Spruce, R. J., Batis, N., Taylor, G. S., Nankivell, P., & Mehanna, H. M. (2019) · Cancers · doi:10.3390/cancers11081115 · Cited by 32
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
Zeng, J., Johnson, A. M., Shufean, M. A., Kahle, M., Yang, D., Woodman, S. E., Vu, T., Moorthy, S., Holla, V. R., & Meric‐Bernstam, F. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00089 · Cited by 31
Davis, A. A., Iams, W. T., Chan, D., Oh, M. S., Lentz, R. W., Peterman, N., Robertson, A., Shah, A., Srivas, R., Wilson, T., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1060 · Cited by 33
Bujak, A. Z., Weng, C.-F., Silva, M. J., Yeung, M. M., Lo, L. L., Ftouni, S., Litchfield, C., Ko, Y.-A., Kuykhoven, K. S., van Geelen, C. T., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003363 · Cited by 33
Self-citationMolecular Profiles of Brain Metastases: A Focus on Heterogeneity
Ali, S., Górska, Z., Duchnowska, R., & Jassem, J. (2021) · Cancers · doi:10.3390/cancers13112645 · Cited by 33
Imaging immunity in patients with cancer using positron emission tomography
Hegi‐Johnson, F., Rudd, S. E., Hicks, R. J., Ruysscher, D. D., Trapani, J. A., John, T., Donnelly, P. S., Blyth, B. J., Hanna, G. G., Everitt, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00263-x · Cited by 33
Hai, L., Li, L., Liu, Z., Tong, Z., & Sun, Y. (2022) · MedComm · doi:10.1002/mco2.134 · Cited by 32
A tale of exosomes and their implication in cancer
Mishra, A., Bharti, P. S., Rani, N., Nikolajeff, F. K., & Kumar, S. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188908 · Cited by 32
Xu, Y., Cai, J., Zhong, K., Wen, Y., Cai, L., He, G., Liao, H., Zhang, C., Fu, S., Chen, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1119744 · Cited by 33
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer
Morganti, S., Parsons, H. A., Lin, N., & Grinshpun, A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00550-1 · Cited by 30
Sorbini, M., Carradori, T., Togliatto, G., Vaisitti, T., & Deaglio, S. (2024) · Biomolecules · doi:10.3390/biom14040498 · Cited by 32
Using circulating tumor cells to inform on prostate cancer biology and clinical utility
Li, J., Gregory, S. G., García-Blanco, M. A., & Armstrong, A. J. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1023430 · Cited by 31
Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma
Klevebring, D., Neiman, M., Sundling, S., Eriksson, L., Darai‐Ramqvist, E., Celebioglu, F., Czene, K., Hall, P. N., Egevad, L., Grönberg, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104417 · Cited by 29
Molecular diagnostics in gastric cancer
Bornschein, J. (2014) · Frontiers in bioscience · doi:10.2741/4210 · Cited by 30
Revealing the Complexity of Breast Cancer by Next Generation Sequencing
Verigos, J., & Magklara, A. (2015) · Cancers · doi:10.3390/cancers7040885 · Cited by 30
Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma
Gangadhar, T. C., Savitch, S. L., Yee, S. S., Xu, W., Huang, A. C. C., Harmon, S., Lieberman, D. B., Soucier, D., Fan, R., Black, T. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12623 · Cited by 39
Nörthen, A., Asendorf, T., Walson, P. D., & Oellerich, M. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.10.011 · Cited by 30
Monitoring colorectal cancer following surgery using plasma circulating tumor DNA
Sun, X., Huang, T., Cheng, F., Huang, K., Liu, M., He, W., Li, M., Zhang, X., Xu, M., Chen, S., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7837 · Cited by 30
Lin, M., Alnaggar, M., Liang, S., Chen, J., Xu, K., Dong, S., Du, D., & Niu, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490874 · Cited by 32
Nakabayashi, M., Kawashima, A., Yasuhara, R., Hayakawa, Y., Miyamoto, S., Iizuka, C., & Sekizawa, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29381-y · Cited by 30
Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives
Perumal, V., Corica, T., Dharmarajan, A., Sun, Z., Dhaliwal, S. S., Dass, C. R., & Dass, J. (2019) · Cancers · doi:10.3390/cancers11030367 · Cited by 31
Rational Design of Framework Nucleic Acids for Bioanalytical Applications
Su, Y., Li, D., Liu, B., Xiao, M., Wang, F., Li, L., Zhang, X., & Pei, H. (2019) · ChemPlusChem · doi:10.1002/cplu.201900118 · Cited by 30
Circulating Tumor Cells in Breast Cancer
Liang, D. H., Hall, C. S., & Lucci, A. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_7 · Cited by 32
Mezzalira, S., Mattia, E. D., Guardascione, M., Fratte, C. D., Cecchin, E., & Toffoli, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215498 · Cited by 31
Chen, Z., Sun, T., Yang, Z., Zheng, Y., Yu, R., Wu, X., Yan, J., Shao, Y. W., Shao, X., Cao, W., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1079 · Cited by 29
Exosomal Del-1 as a Potent Diagnostic Marker for Breast Cancer: Prospective Cohort Study.
Lee, S. J., Lee, J., Jung, J., Park, H., Moon, P.-G., Yee, S.-C., & Baek, M.-C. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.02.002 · Cited by 18
Genomic tumor evolution of breast cancer
Sato, F., Saji, S., & Toi, M. (2015) · Breast Cancer · doi:10.1007/s12282-015-0617-8 · Cited by 31
Dekaliuk, M. O., Qiu, X., Troalen, F., Busson, P., & Hildebrandt, N. (2019) · ACS Sensors · doi:10.1021/acssensors.9b01420 · Cited by 33
Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities
Katopodi, X.-L., Begik, O., & Novoa, E. M. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf128 · Cited by 29
The possibility of clinical sequencing in the management of cancer
Kou, T., Kanai, M., Matsumoto, S., Okuno, Y., & Muto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw018 · Cited by 30
Jiang, T., Li, X., Wang, J., Su, C., Han, W., Zhao, C., Wu, F., Gao, G., Li, W., Chen, X., et al. (2017) · Theranostics · doi:10.7150/thno.21687 · Cited by 29
Park, Y. R., Kim, Y., Lee, H. Y., Lee, G. E., Lee, G. E., Lee, J.-E., & Kim, Y. (2018) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2018.61.3.328 · Cited by 30
Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers
Swiecicki, P. L., Brennan, J. R., Mierzwa, M. L., Spector, M. E., & Brenner, J. C. (2018) · The Laryngoscope · doi:10.1002/lary.27725 · Cited by 30
Cui, H., Li, R., Du, J., Meng, Q., Wang, Y., Wang, Z., Chen, F., Dong, W., Cao, J., Yang, L., et al. (2019) · Talanta · doi:10.1016/j.talanta.2019.05.001 · Cited by 29
Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma
Terasawa, H., Kinugasa, H., Ako, S., Hirai, M., Matsushita, H., Uchida, D., Tomoda, T., Matsumoto, K., Horiguchi, S., Kato, H., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1638685 · Cited by 31
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer
Davidson, B. A., Croessmann, S., & Park, B. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01422-w · Cited by 29
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
Chin, Y. M., Shibayama, T., Chan, T., Otaki, M., Hara, F., Kobayashi, T., Kobayashi, K., Hosonaga, M., Fukada, I., Inagaki, L., et al. (2022) · Cancer Science · doi:10.1111/cas.15304 · Cited by 30
DNA markers in molecular diagnostics for hepatocellular carcinoma
Su, Y., Lin, S. Y., Song, W., & Jain, S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.946908 · Cited by 28
Minimal residual disease testing in hematologic malignancies and solid cancer
Lassoued, A. B., Nivaggioni, V., & Gabert, J. A. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.927311 · Cited by 29
Genomically personalized therapy in head and neck cancer
Aung, K. L., & Siu, L. L. (2016) · Cancers of the Head & Neck · doi:10.1186/s41199-016-0004-y · Cited by 32
Cabel, L., Decraene, C., Bièche, I., Pierga, J., Bennamoun, M., Fuks, D., Ferraz, J., Lefèvre, M., Baulande, S., Bernard, V., et al. (2019) · Cancers · doi:10.3390/cancers11030396 · Cited by 29
Major milestones in translational oncology
Dragani, T. A., Castells, A., Kulasingam, V., Diamandis, E. P., Earl, H. M., Iams, W. T., Lovly, C. M., Sedelaar, J. P. M., & Schalken, J. A. (2016) · BMC Medicine · doi:10.1186/s12916-016-0654-y · Cited by 31
Pu, X., Zhang, C., Ding, G., Gu, H., Lv, Y., Shen, T., Pang, T., Cao, L., & Jia, S. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101847 · Cited by 28
Hou, H., Yang, X., Zhang, J., Zhang, Z., Xu, X., Zhang, X., Zhang, C., Liu, D., Yan, W., Zhu, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14962-0 · Cited by 28
Zhang, Y., Lai, X., Zeng, Q., Li, L., Lin, L., Li, S., Liu, Z., Su, C., Qi, M., & Guo, Z. (2018) · Laser Physics · doi:10.1088/1555-6611/aa9d6d · Cited by 28
Keup, C., Storbeck, M., Hauch, S., Hahn, P. F., Sprenger‐Haussels, M., Tewes, M., Mach, P., Hoffmann, O., Kimmig, R., & Kasimir‐Bauer, S. (2019) · Cancers · doi:10.3390/cancers11020238 · Cited by 28
Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 28
Tian, X., Ge, D., Zhang, F., Zhang, B., Bai, W., Xu, X., Li, Z., Cao, Y., Li, P., Zou, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33362 · Cited by 28
Gill, A. B., Rundo, L., Wan, J. C. M., Lau, D., Zawaideh, J. P., Woitek, R., Zaccagna, F., Beer, L., Gale, D. G., Sala, E., et al. (2020) · Cancers · doi:10.3390/cancers12123493 · Cited by 28
Self-citationApplications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Pal, A., Shinde, R., Miralles, M. S., Workman, P., & Bono, J. S. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00489-x · Cited by 28
Groeneweg, J. W., Roze, J. F., Peters, E. D. J., Sereno, F., Brink, A. G. J., Paijens, S. T., Nijman, H. W., van Meurs, H. S., van Lonkhuijzen, L. R. C. W., Piek, J. M. J., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.027 · Cited by 28
Zengin, Z. B., Weipert, C. M., Salgia, N., Dizman, N., Hsu, J., Meza, L., Chehrazi‐Raffle, A., Muddasani, R., Salgia, S. K., Malhotra, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0572 · Cited by 29
Bruscaggin, A., di Bergamo, L. T., Spina, V., Hodkinson, B. P., Forestieri, G., Bonfiglio, F., Condoluci, A., Wu, W., Pirosa, M. C., Faderl, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004528 · Cited by 28
Fujisawa, R., Iwaya, T., Endo, F., Idogawa, M., Sasaki, N., Hiraki, H., Tange, S., Hirano, T., Koizumi, Y., Abé, M., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab088 · Cited by 29
Kavan, S., Kruse, T. A., Vogsen, M., Hildebrandt, M. G., & Thomassen, M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10023-9 · Cited by 30
Wang, R., Zhao, Y., Wang, Y., Zhao, Z., Chen, Q., Duan, Y., Xiong, S., Luan, Z., Wang, J., & Cheng, B. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000487 · Cited by 30
Mjahed, R. B., Astaras, C., Roth, A. D., & Koessler, T. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00982-0 · Cited by 28
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic
Beltran, H., Antonarakis, E. S., Morris, M. J., & Attard, G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159248 · Cited by 29
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer
Ross, K., Pailler, E., Faugeroux, V., Taylor, M., Oulhen, M., Auger, N., Planchard, D., Soria, J., Lindsay, C. R., Besse, B., et al. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1111139 · Cited by 31
Effect of deoxyribonuclease I treatment for dementia in end-stage Alzheimer’s disease: a case report
Tetz, V., & Tetz, G. V. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-0931-6 · Cited by 27
Wang, Y., Zhou, Y., & Hu, Z. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0029 · Cited by 28
Farooq, M., & Herman, J. G. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0704 · Cited by 28
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27
Liquid biopsy: creating opportunities in brain space
Trivedi, R., & Bhat, K. P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02446-0 · Cited by 27
Salter, H., & Holland, R. L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12234 · Cited by 27
Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer
Han, H. S., & Magliocco, A. M. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.02.016 · Cited by 27
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 28
Cell-free DNA as a post-treatment surveillance strategy: current status
Burgener, J., Rostami, A., Carvalho, D. D. D., & Bratman, S. V. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.009 · Cited by 26
CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy
Mintz, R. L., Gao, M. A., Lo, K., Lao, Y., Li, M., & Leong, K. W. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800132 · Cited by 27
Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling
Scherer, F. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_11 · Cited by 26
Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine
Kerachian, M. A., Poudineh, A., & Thiery, J. P. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102827 · Cited by 27
Development and validation of a targeted gene sequencing panel for application to disparate cancers
McCabe, M. J., Gauthier, M.-E. A., Chan, C., Thompson, T. J., Sousa, S. M. C. D., Puttick, C., Grady, J. P., Gayevskiy, V., Tao, J., Ying, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52000-3 · Cited by 27
Self-citationde Kruijff, I. E., Beije, N., Martens, J. W. M., de Wit, R., Boormans, J. L., & Sleijfer, S. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.01.003 · Cited by 27
Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies
Sellmyer, M. A., Lee, I. K., & Mankoff, D. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262484 · Cited by 27
Yu, F., Makrigiorgos, A., Leong, K. W., & Makrigiorgos, G. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.037 · Cited by 27
Wang, J., Han, X., & Sun, Y. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-0253-7 · Cited by 27
Potential clinical applications of circulating cell-free DNA in ovarian cancer patients
Barbosa, A. P. F., Peixoto, A., Pinto, P., Pinheiro, M., & Teixeira, M. R. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.5 · Cited by 27
Mithraprabhu, S., Hocking, J., Ramachandran, M., Choi, K., Klarica, D., Khong, T. T., Reynolds, J., & Spencer, A. G. (2019) · Cancers · doi:10.3390/cancers11070917 · Cited by 28
Stereotactic body radiation therapy for spinal metastases: A new standard of care
Sacino, A. N., Chen, H., Sahgal, A., Bettegowda, C., Rhines, L. D., Maralani, P. J., & Redmond, K. J. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noad225 · Cited by 26
Gu, T., Xiao, Y.-L., & Shao, Z.-M. (2024) · Precision Medicine and Engineering · doi:10.1016/j.preme.2024.100006 · Cited by 25
Tang, M. E., Dahlgren, M., Brueffer, C., Tjitrowirjo, T., Winter, C., Chen, Y., Olsson, E., Wang, K., Törngren, T., Sjöström, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5951 · Cited by 27
Feasibility of Cell-Free Circulating Tumor DNA Testing for Lung Cancer
Santarpía, M., Karachaliou, N., González‐Cao, M., Altavilla, G., Giovannetti, E., & Rosell, R. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.16.6 · Cited by 26
Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Lewis, A. R., Valle, J. W., & McNamara, M. G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7175 · Cited by 31
Baird, R. D., van Rossum, A. G. J., Oliveira, M., Beelen, K. J., Gao, M., Schrier, M., Mandjes, I. A. M., García-Corbacho, J., Vallier, A.-L., Dougall, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0508 · Cited by 28
Self-citationChen, Y., Liao, L., Wu, Z., Yang, Q., Guo, J., He, J., Wang, S., Xu, X., Wu, J., Pan, F., et al. (2020) · Aging · doi:10.18632/aging.102686 · Cited by 26
Evaluating liquid biopsies for methylomic profiling of prostate cancer
Silva, R., Moran, B., Russell, N. M., Fahey, C., Vlajnic, T., Manecksha, R. P., Finn, S. P., Brennan, D. J., Gallagher, W. M., & Perry, A. S. (2020) · Epigenetics · doi:10.1080/15592294.2020.1712876 · Cited by 24
Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies
Leick, K. M., Kazarian, A. G., Rajput, M., Tomanek‐Chalkley, A., Miller, A., Shrader, H. R., McCarthy, A., Coleman, K. L., Kasi, P. M., & Chan, C. H. F. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08832-9 · Cited by 26
Vellichirammal, N. N., Chaturvedi, N. K., Joshi, S. S., Coulter, D. W., & Guda, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.015 · Cited by 25
Grassi, T., Harris, F. R., Smadbeck, J. B., Murphy, S. J., Block, M. S., Multinu, F., Klein, J. L. S., Zhang, P., Karagouga, G., Liu, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252390 · Cited by 25
Metadata
- Authors
- Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., & Rosenfeld, N.
- Affiliations
- University of Cambridge (GB)
- National Health Service (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-28
- Volume
- 368
- Issue
- 13
- Pages
- 1199-1209
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140575188
- Cited by
- 2,207
- References
- 44
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 106 · 2023: 109 · 2022: 169 · 2021: 180 · 2020: 197 · 2019: 220 · 2018: 197 · 2017: 224 · 2016: 204 · 2015: 195 · 2014: 135 · 2013: 82
- FWCI
- 72.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (11906, 16942, 22310)
- National Institute for Health and Care Research (NF-SI-0611-10154)
- NIHR Cambridge Biomedical Research Centre
- Cancer Research UK Cambridge Institute, University of Cambridge
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- circulating tumor DNA, metastatic breast cancer, liquid biopsy, CA15-3, circulating tumor cells, treatment response monitoring, tumor burden, somatic alterations, circulating biomarkers, early detection of treatment response
- MeSH terms
- Breast Neoplasms, DNA, Neoplasm, Female, Humans, Mutation, Neoplasm Metastasis, Prognosis, Radiography, Sensitivity and Specificity, Biomarkers, Tumor, Sequence Analysis, DNA, Mucin-1, Tumor Burden, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
